Results 31 to 40 of about 55,779 (204)
Expert Review of Vaccines, 2008 Dengue is an arthropod-borne infection caused by a flavivirus and spread by the Aedes mosquitoes. Many of the countries where dengue is endemic are popular tourist destinations and the disease is an increasingly important problem encountered by international travelers.
Annelies, Wilder-Smith +1 more
openaire +2 more sources
Human Vaccines & Immunotherapeutics, 2014 Dengue has emerged as one of the major global public health problems. The disease has broken out of its shell and has spread due to increased international travel and climatic changes. Globally, over 2.5 billion people accounting for >40% of the world's population are at risk from dengue.
Harashish, Jindal +3 more
openaire +2 more sources
Illness in Returned Travelers and Immigrants/Refugees: The 6-Year Experience of Two Australian Infectious Diseases Units. [PDF]
, 2008 BACKGROUND: Data comparing returned travelers and immigrants/refugees managed in a hospital setting is lacking. METHODS: We prospectively collected data on 1,106 patients with an illness likely acquired overseas who presented to two hospital-based ...
Brown, G V +4 more
core +2 more sources
Bioethics of establishing a CHIM model for dengue vaccine development
International Journal of Infectious Diseases, 2019 Introduction: Controlled human infection models (CHIM) have been used in vaccine development to up-select and down-select potential vaccine candidates and to provide proof of vaccine efficacy, and have also been used as a basis for licensure of vaccines ...
Anuradha Rose, Amrita Sekhar
doaj +1 more source
Outlook for a dengue vaccine [PDF]
Clinical Microbiology and Infection, 2014 Dengue is an increasing medical problem in subtropical and tropical countries. The search for a safe and effective vaccine is complicated by the fact that there are four types of dengue virus and that, if a vaccine is live attenuated, it should be proven not to cause the life-threatening form of dengue, dengue haemorrhagic fever.
openaire +2 more sources
Microorganisms, 2019 With one vaccine on the market and others in clinical trials, policy makers in dengue endemic regions face the decision of whether to introduce a dengue vaccine in their communities.
Elizabeth McMahon +14 more
doaj +1 more source
Dengue vaccine development: Global and Indian scenarios
International Journal of Infectious Diseases, 2019 India is home to nearly a third of the global population at risk of dengue, a viral disease caused by four antigenically and genetically distinct dengue viruses.
Sathyamangalam Swaminathan, Navin Khanna
doaj +1 more source
Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis. [PDF]
, 2012 BackgroundThe plaque reduction neutralization test (PRNT) remains the gold standard for the detection of serologic immune responses to dengue virus (DENV).
Cummings, Derek AT +3 more
core +3 more sources
Vaccines licensed and in clinical trials for the prevention of dengue
Human Vaccines & Immunotherapeutics, 2017 Dengue has become a major global public health threat with almost half of the world's population living in at-risk areas. Vaccination would likely represent an effective strategy for the management of dengue disease in endemic regions, however to date ...
J. Torresi, G. Ebert, M. Pellegrini
doaj +1 more source
Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity
Frontiers in Immunology, 2020 Dengue is one of the most frequently transmitted mosquito-borne diseases in the world, which creates a significant public health concern globally, especially in tropical and subtropical countries.
Abdullah M. Izmirly +10 more
doaj +1 more source